Why the study?
Does chronic moxonidine therapy reduce resting peripheral sympathetic activity and vascular resistance in newly diagnosed patients with essential hypertension?
Population
12 newly diagnosed patients with essential hypertension
Comparison
Chronic oral moxonidine therapy at increasing… vs Baseline (no therapy)
Design
Cohort
Follow-up
At least 2 months
Authors
Loading...
Moxonidine was associated with reduced sympathetic activity in hypertension; leaves open outcome benefits and should not change practice.
Does chronic moxonidine therapy reduce resting peripheral sympathetic activity and vascular resistance in newly diagnosed patients with essential hypertension?
Chronic moxonidine therapy effectively inhibits resting sympathetic vasoconstrictor drive and reflex responses in essential hypertension, with the most significant reductions occurring at a dose of 200 microg daily.
Greenwood et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: